Fortune released its annual 50 Most Powerful Women list on Thursday.

While the first-place finisher — General Motor’s CEO Mary Barra — wasn’t surprising, one woman in the middle of the pack undoubtedly raised a few eyebrows: Mylan CEO Heather Bresch.

Ms. Bresch — who ranked No. 23, one notch down from last year — has been roundly vilified in recent weeks as the head of the drug company that raised the price of the EpiPen allergy treatment some 500 percent in recent years, making it unaffordable for many who rely on the potentially life-saving device.

“Some might wonder why Fortune chose to keep her on the list at all,” Fortune wrote in a lengthy explainer. “Or why we didn’t drop her further down the ranking to reflect the universally negative backlash her actions have provoked.”

Advertise with us

Strictly by the numbers, as the head of a $9.4 billion company and the only woman to ever run a Fortune 500 pharmaceutical firm, she deserved a spot, the magazine said.

“The Most Powerful Women list is a ranking of just that, the female executives with the most power and influence in business today,” Fortune said.

“There are no criteria for whether they wield that power virtuously or not.”

Fortune also noted that until Mylan, which has its administrative offices in Cecil, was accused recently of price-gouging patients, Ms. Bresch “wore EpiPen’s success as a badge of pride.”

“Mylan executives give her all the credit for recognizing the potential of the epinephrine auto-injector when Mylan acquired it” in 2007, the magazine said, noting that EpiPen sales soared from around $200 million back then to some $1 billion by 2014.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066